Log in to search using one of your social media accounts:

 

Highland Hospital Offers Nitrous Oxide as Pain Management Option for Maternity Patients
Highland Hospital is now the first hospital in the Rochester region to offer nitrous oxide as an additional pain relief option to mothers in labor. (Source: University of Rochester Medical Center Press Releases)
Source: University of Rochester Medical Center Press Releases - February 16, 2018 Category: Universities & Medical Training Authors: University of Rochester Medical Center Source Type: news

Pacira shares fall after FDA committee rejects expanded use for Exparel pain drug
Shares in Pacira Pharmaceuticals (NSDQ:PCRX) fell nearly -16% today after a panel of experts convened by the FDA voted against an expanded use for Pacira’s injectable pain drug. The pharmaceutical company previously submitted an application seeking to use the local anesthetic as a regional pain-killer. Get the full story at our sister site, Drug Delivery Business News. The post Pacira shares fall after FDA committee rejects expanded use for Exparel pain drug appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - February 16, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Food & Drug Administration (FDA) Pain Management Pharmaceuticals Regulatory/Compliance Wall Street Beat Pacira Pharmaceuticals Source Type: news

Oxfam ’s Sexual Abuse Episode Must Inspire a Culture Shift
A UN peacekeeper holds a child as her mother is helped down from a relocation truck in Port-au-Prince, Haiti. Credit: UN Photo/Logan AbassiBy Siddharth ChatterjeeNAIROBI, Kenya, Feb 16 2018 (IPS)Sexual abuse allegations against Oxfam staff, and failings in the charity’s response to them, delivered a body blow to an organisation renowned for years of humanitarian and development work. At the very least the accusations will leave a stain on the reputation of a charity that works in some of the toughest environments in the world, and has made a positive difference in the lives of the most vulnerable. The Oxfam reports c...
Source: IPS Inter Press Service - Health - February 16, 2018 Category: International Medicine & Public Health Authors: Siddharth Chatterjee Tags: Aid Gender Gender Violence Global Headlines Health Human Rights TerraViva United Nations Source Type: news

Cochrane Evidence used in new WHO guideline on intrapartum care for a positive birth experience
The World Health Organization (WHO) has issued new recommendationsto establish global care standards for healthy pregnant women and reduce unnecessary medical interventions.Worldwide, an estimated 140 million births take place every year. Most of these occur without complications for women and their babies. Yet, over the past 20 years, practitioners have increased the use of interventions that were previously only used to avoid risks or treat complications, such as oxytocin infusion to speed up labour or caesarean sections.“We want women to give birth in a safe environment with skilled birth attendants in well-equipp...
Source: Cochrane News and Events - February 15, 2018 Category: Information Technology Authors: Muriah Umoquit Source Type: news

American Pain Society Slams McCaskill Report on Opioids American Pain Society Slams McCaskill Report on Opioids
The APS says the report's conclusions are'simplistic, misleading and insulting'and damage their reputation for scientific integrity and advocacy on behalf of pain management doctors and patients.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 15, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Relievant touts 1-year Intracept trial results
Relievant Medsystems today released the results from the Smart trial of its Intracept intraosseous nerve ablation system exploring its usefulness at treating chronic lower back pain, touting significant decreases in pain from baseline at three months. The Intracept system is designed to use radio frequency energy delivered through specially designed instruments during a minimally invasive surgical procedure to access and ablate the basivertebral nerve to prevent it from transmitting pain signals. Results from the trial were reported in the European Spine Journal, the Sunnyvale, Calif.-based company said. “The In...
Source: Mass Device - February 12, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Pain Management Spinal Relievant Medsystems Inc. Source Type: news

BDSI reaches settlement with generic drug giant Teva
Raleigh-based BioDelivery Sciences International (Nasdaq: BDSI) has settled the last of its outstanding patent litigation filed against generic manufacturing giant Teva Pharmaceuticals. BDSI said Tuesday that the company has entered into a settlement agreement with Teva that resolves its pending patent litigation against Teva related to BDSI's pain management product Belbuca.  Teva had a manufacturing operation in the Triad in Browns Summit that employed 200 from 2011 until 201 4, when Procter… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 8, 2018 Category: Pharmaceuticals Authors: Jennifer Henderson Source Type: news

PAINWeekEnd in Scottsdale, Arizona, Offers CE/CME Education to Address...
Two Days of Pain Management for the Main Street Practitioner, March 10-11; mingle with faculty and attendees, learn and earn up to 12.0 AMA PRA Category 1 credits for $199(PRWeb February 08, 2018)Read the full story at http://www.prweb.com/releases/2018/02/prweb15177734.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 8, 2018 Category: Pharmaceuticals Source Type: news

This Teacher and Survivor is on a Mission to End Gender-Based Violence
February 07, 2018Sylvia is helping young people protect themselves from violence, access health services, and stay in school.Wokuri Sylvia is a 45-year-old survivor of gender-based violence (GBV) and today is a primary school teacher in Mbale,Uganda, on a mission to keep girls and boys safe from violence.As a teenager in rural Mbale, Sylvia experienced her parents ’ horrible divorce. With no secure social support, she lost her teen years to turmoil.“When my parents divorced, it was horrible,” says Sylvia. “Our family broke up. My siblings stayed with different relatives. It was brutal as a teenager ...
Source: IntraHealth International - February 7, 2018 Category: International Medicine & Public Health Authors: intrahealth Source Type: news

BDSI reaches settlement with generic drug giant Teva
Raleigh-based BioDelivery Sciences International (Nasdaq: BDSI) has settled the last of its outstanding patent litigation filed against generic manufacturing giant Teva Pharmaceuticals. BDSI said Tuesday that the company has entered into a settlement agreement with Teva that resolves its pending patent litigation against Teva related to BDSI's pain management product Belbuca.  The patent litigation – filed by BDSI in the U.S. District Court for the District of Delaware early last year – alleged… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 7, 2018 Category: Pharmaceuticals Authors: Jennifer Henderson Source Type: news

Portal Instruments uses speed to tackle needle-free drug delivery
Nobody likes to be on the receiving end of a shot. Studies have found that needle anxiety keeps people from getting important medications, like the flu vaccine, and can even stop people from taking self-injected drugs to manage chronic illnesses. That’s a problem that Portal Instruments hopes to solve with its needle-free injection system. “By the time you are done with the injection, the patient doesn’t really realize that he or she has injected a drug,” CEO Patrick Anquetil told Drug Delivery Business News. Get the full story at our sister site, Drug Delivery Business News. The post...
Source: Mass Device - February 6, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Pain Management Pharmaceuticals Research & Development Wall Street Beat portal instruments Source Type: news

Zynex introduces the NeuroMove(TM) Device to its expanding sales force
LONE TREE, Colo., Feb. 1, 2018 -- (Healthcare Sales & Marketing Network) -- Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilita... Devices, Product Launch Zynex, electrotherapy, NeuroMove (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 1, 2018 Category: Pharmaceuticals Source Type: news

A future of better pain management without codeine awaits Australia | Malcolm Hogg
Codeine is old hat yet still widely used in the community. We need better informed consumers with better educated and supported GPs and pharmacistsCodeine restriction is in keeping with our evolving understanding of pain and its best management.My earliest memory of pain relates to Bex powders, which sat on our windowsill above the kitchen sink and were used daily to help with headaches, fevers and other pain. “Take a cup of tea, a Bex and a good lie down” was the approach to pain in the 1960s.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - January 31, 2018 Category: Science Authors: Malcolm Hogg Tags: Health Drugs Australia news Science Doctors GPs Pharmaceuticals industry Source Type: news

Ensysce Bioscience wins fast track status for abuse-deterrent oxycodone
Ensysce Biosciences said this week that its extended-release oxycodone prodrug won fast track status from the FDA. The San Diego, Calif.-based company is developing the abuse-deterrent drug as a pain management therapy for people with moderate to severe chronic pain. Get the full story at our sister site, Drug Delivery Business News. The post Ensysce Bioscience wins fast track status for abuse-deterrent oxycodone appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - January 30, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Food & Drug Administration (FDA) Pain Management Pharmaceuticals Regulatory/Compliance ensyscebiosciences Source Type: news

Ketamine for Pain Management Ketamine for Pain Management
Ketamine is increasingly used as an off-label analgesic, but are you aware of the potential side effects?Pain Management Nursing (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 30, 2018 Category: Consumer Health News Tags: Nursing Journal Article Source Type: news

Accuray touts trigeminal neuralgia CyberKnife study results
This study is important because it reinforces that CyberKnife SRS provides unique benefits in the treatment of TN. Pain management goals were achieved and bothersome complications were rare even though a less invasive approach to delivering radiation was used. Importantly, we used a consistent treatment protocol for each patient that resulted in reproducible outcomes. This should provide confidence to other clinicians that they, too, can achieve similar clinical results,” Dr. Pantaleo Romanelli of Milan, Italy’s Centro Diagnostico Italiano said in a prepared statement. Data from the 138-patient study indic...
Source: Mass Device - January 29, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Neurological Pain Management Accuray Inc. Source Type: news

Electrocore wins FDA nod for GammaCore acute migraine treatment indication
Electrocore said today it won FDA 510(k) clearance for its GammaCore device, expanding indications to include the acute treatment of pain associated with migraines in adult patients. The Basking Ridge, N.J.-based company’s GammaCore device is a non-invasive, hand-held vagus nerve stimulation device designed for the reduction of pain. The system is intended to be applied to the neck and applies a patented electrical stimulation through the skin to activate the vagus nerve. “Migraine is a debilitating disease affecting 39 million Americans, the majority of whom do not seek medical care for their pain. W...
Source: Mass Device - January 29, 2018 Category: Medical Devices Authors: Fink Densford Tags: 510(k) Food & Drug Administration (FDA) Neurological Neuromodulation/Neurostimulation Pain Management Regulatory/Compliance electroCore Source Type: news

J & J ’ s DePuy Synthes touts anterior-approach results in comparative THA study
This study builds on the mounting evidence that the anterior approach supports the goals of improving outcomes, optimizing the patient experience and reducing the overall cost of care,” DePuy Synthes health economics and market access US head and study co-author Samir Bhattacharyya said in a press release. Last month, DePuy Synthes said it closed its sale of Prodisc assets to Centinel Spine for an undisclosed amount. The post J&J’s DePuy Synthes touts anterior-approach results in comparative THA study appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - January 29, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Orthopedics depuysynthes johnsonandjohnson Source Type: news

Bioness Receives Health Canada Approval for StimRouter Neuromodulation System
Device for chronic pain management now approved to market in Canada VALENCIA, Calif., Jan. 29, 2018 -- (Healthcare Sales & Marketing Network) -- Bioness, Inc., the leading provider of cutting edge, clinically supported rehabilitation therapies, today a... Devices, Neurology, Regulatory Bioness, StimRouter, Neuromodulation (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 29, 2018 Category: Pharmaceuticals Source Type: news

How Genetic Testing Saved My Life from Debilitating Clinical Depression
The psychologist’s qualifications are proudly displayed in frames on his wall: a doctorate in clinical psychology, board certifications in clinical psychology and clinical neuropsychology. Maybe this means he can help me. I need an expert on the human mind to help me figure out why mine cannot cooperate, why consciousness has become so unbearable for me.   I am sitting on the couch in his office. He sits in his desk chair, awaiting my gaze to meet his. When I do, he delivers his first question: “Have you been considering suicide?” I am at the brink of desperation, and I figure I must be totally ho...
Source: Psych Central - January 27, 2018 Category: Psychiatry Authors: Kristen Davis Tags: Antidepressants Depression Genetics Medications Mood Stabilizers Neuroscience Personal Stories Self-Esteem Stigma Suicide Treatment Blame Clinical Depression Compassion Disease Model Dopamine Genetic Research genetic test Source Type: news

Surgery patients in enhanced recovery program leave hospital sooner, take fewer opioids
(American Society of Anesthesiologists) Colorectal and bariatric surgery patients benefited from an enhanced recovery after surgery (ERAS) program, leaving the hospital sooner and requiring fewer opioids to control pain, according to new research presented at the American Society of Anesthesiologists PRACTICE MANAGEMENT 2018 meeting. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 26, 2018 Category: International Medicine & Public Health Source Type: news

Cefaly touts trial data showing outperformance of drugs for migraine abortion treatment
Cefaly yesterday released data from a trial of its Cefaly Acute device designed for the acute treatment of migraines, touting that its migraine abortion capabilities outperformed current published data on triptans and other medical drugs under investigation for the acute treatment of migraines. The New York City-based company’s flagship Cefaly Acute device is FDA-approved as an external trigeminal nerve stimulation device designed to prevent frequent episodic migraines. The device can also help patients who are normally unaffected by oral migraine medication. Based on data from the trial, Cefaly said it is planning t...
Source: Mass Device - January 25, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Pain Management Cefaly Source Type: news

How conversations with virtual people could help mitigate the opioid crisis
It often starts in the doctor’s office or the emergency room. A patient has broken their leg and will be in pain for weeks. Another patient has had back surgery and is on their way home, but it will take time before they’re fully recovered. A third patient has returned for a consult about the constant pain that keeps them awake at night. All of these patients could be prescribed opioids. But as the addiction crisis rages on, healthcare professionals have become wary of doling out addictive painkillers. Research has shown that the slippery slope of addiction often begins with a perfectly legal prescription. That...
Source: Mass Device - January 25, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Healthcare Reform Hospital Care Pain Management Pharmaceuticals kognito Source Type: news

Ocular Therapeutix plans $32.5m public offering to fund NDA resubmission for Dextenza
Updated to include the offering’s pricing information. Ocular Therapeutix (NSDQ:OCUL) said today that it plans to launch an underwritten public offering of 6.5 million shares of common stock at $5.00 apiece to help fund the resubmission of its new drug application for Dextenza, an ocular post-surgical pain-relief implant that was rejected by the FDA last year. The Bedford, Mass.-based company said it will also offer underwriters a 30-day option to buy an additional 15% of the shares in the offering on the same terms. Get the full story at our sister site, Drug Delivery Business News. The...
Source: Mass Device - January 25, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Funding Roundup Optical/Ophthalmic Pain Management Pharmaceuticals Regulatory/Compliance Surgical Wall Street Beat oculartherapeutix Source Type: news

FDA, FTC warn companies over deceptive opioid cessation products
The FDA and the Federal Trade Commission have posted joint warning letters to companies that make and distribute opioid cessation products. The two watchdogs warned that the companies are illegally marketing their unapproved products as treatments or even cures for people with opioid addiction and withdrawal. Selling unapproved products as therapies for opioid addiction is a violation of the Federal Food, Drug and Cosmetic Act and also violates the Federal Trade Commission Act, according to the FDA and FTC. Get the full story at our sister site, Drug Delivery Business News. The post FDA, FTC warn companies over deceptive o...
Source: Mass Device - January 24, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Food & Drug Administration (FDA) Pain Management Pharmaceuticals Regulatory/Compliance Federal Trade Commission (FTC) Source Type: news

Adhesive Considerations for Direct-Skin Wearable Medical Technologies
In addition to caring for the sick, today’s medical providers are also heavily focused on prevention, patient education, and health and wellness strategies. As part of this newer approach to healthcare, providers are implementing ways to deliver additional care options that are both easily accessible and more affordable. Of these, one of the fastest growing and most widely adopted is wearable medical technologies. Wearable medical technologies not only provide support for care related to acute and chronic medical conditions, but also for disease prevention and lifestyle choices. They can monitor health, remind patien...
Source: MDDI - January 22, 2018 Category: Medical Devices Authors: Janet Page Tags: MD & M West (Anaheim) Adhesives Source Type: news

Braeburn dealt setback over monthly, weekly opioid abuse therapy
The FDA has issued a complete response letter to Braeburn Pharmaceuticals, denying its application for an investigational weekly and monthly buprenorphine depot injection designed to treat adults with opioid use disorder. The company reported that the dreaded CRL does not request additional clinical studies, but Braeburn did not elaborate as to what sort of additional information the FDA needs to move the application forward. Get the full story at our sister site, Drug Delivery Business News. The post Braeburn dealt setback over monthly, weekly opioid abuse therapy appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - January 22, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pain Management Pharmaceuticals Regulatory/Compliance Braeburn Pharmaceuticals Source Type: news

Holistic treatment for tension headaches: Manage pain, regain functionality and quality of life with aerobic exercise and Body Awareness Therapy
(Natural News) Aerobic exercise and body awareness therapy (BAT) may help boost pain management, functionality, and quality of life in patients suffering from tension headaches minus the potential side effects associated with drug treatments, a study published in the African Journal of Traditional, Complementary and Alternative Medicines revealed. A team of researchers from turkey’s premiere universities examined 60... (Source: NaturalNews.com)
Source: NaturalNews.com - January 22, 2018 Category: Consumer Health News Source Type: news

7 Simple Ways to Motivate Yourself to Exercise
If one of your New Year’s resolutions was to get in shape, now comes the hard part: sticking with it. This is the time when many of us begin to see our efforts derailed by an array of obstacles, including jobs, family responsibilities, a dislike of exercise or simple inertia. But there are ways to avoid these exercise off-ramps. In my book, Fitter Faster, I share seven science-backed measures that can help you stay motivated and increase your odds of long-term success. Seek instant gratification As important as the long-term health benefits of exercise are, simply being aware of them isn’t enough to motivate mo...
Source: TIME: Health - January 19, 2018 Category: Consumer Health News Authors: Robert J. Davis Tags: Uncategorized Exercise exercise tips exercise tips for beginners Exercise/Fitness fitter faster healthytime how to build self discipline to exercise how to exercise willpower workout tips workout tips for beginners Source Type: news

NeuroMetrix, GSK ink development deal for Quell wearable pain-relief tech
Shares in NeuroMetrix (NSDQ:NURO) soared this morning after the company announced it would partner with GlaxoSmithKline (NYSE:GSK) to expand development of NeuroMetrix’s Quell wearable pain-relief device. According to the terms of the deal, GSK’s consumer healthcare business will have exclusive rights to the Quell system for markets outside of the U.S., while NeuroMetrix will retain ownership of the device within the U.S. Get the full story at our sister site, Drug Delivery Business News. The post NeuroMetrix, GSK ink development deal for Quell wearable pain-relief tech appeared first on Mas...
Source: Mass Device - January 17, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: mHealth (Mobile Health) Pain Management Research & Development Wall Street Beat GlaxoSmithKline plc Neurometrix Source Type: news

Now, Safer Deliveries for Women in Tajikistan
January 16, 2018In just a year, home births in Bokhtar District have been cut in half.“I delivered my oldest daughter at home,” says Gulrukhsor Talbieva. “I’d never heard about the maternity hospital.”  Gulrukhsor Talbieva, now a 26-year-old mother of five, lives in Lohuti village in Tajikistan ’s remote Bokhtar district.She also delivered her second baby, a son, at home and had a terrible headache that lasted for days. She didn ’t know it at the time, but she had eclampsia, a life-threatening condition." I'd never heard about the maternity hospital. "  “I...
Source: IntraHealth International - January 17, 2018 Category: International Medicine & Public Health Authors: cbales Source Type: news

Abbott, Nevro tout spinal cord stimulation tech
Abbott (NYSE:ABT) and Nevro (NYSE:NVRO) touted their spinal cord stimulation technologies at the annual North American Neurological Society meeting in Las Vegas. Two-year data from Abbott’s 42-patient Sunburst study revealed that a majority of patients chose its BurstDR therapy when given the choice during the long-term follow-up period and that stimulation from BurstDR provided pain relief through 24 months. Patient preference for Abbott’s BurstDR system grew over time, the company pointed out – 68% of patients chose BurstDR at 12 months compared to 81% at two years. “The BurstDR waveform is b...
Source: Mass Device - January 16, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Neurological Neuromodulation/Neurostimulation Pain Management Wall Street Beat Abbott nevro Source Type: news

Factors Predictive of Patients' Satisfaction of Pain Control Factors Predictive of Patients' Satisfaction of Pain Control
Find out how these factors may impact the perception of pain control among hospitalized patients.Pain Management Nursing (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 16, 2018 Category: Consumer Health News Tags: Nursing Journal Article Source Type: news

What Treatment is Recommended for Common Headaches?
Discussion Headache is pain in the scalp, forehead, orbits and temple. Facial and neck pain are usually excluded from this definition. It is a common problem with more than 6 million pediatric patients having migraine. Headaches can also have co-morbidities and more than 1 primary headache type can co-exist. The costs are high both economically and in the quality of life for the patients and families. A review of common headache types and indications for neuroimaging can be found here. Treatment is necessarily multi-pronged. Patients should understand their diagnosis so they can understand what reasonably can be expected...
Source: PediatricEducation.org - January 15, 2018 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Developing a Medtech Product? Consider These 4 Essentials
Years ago, when Darren Saravis invented the SKB guitar effects pedalboard, he was met with quick success. The experience, however, prompted Saravis to envision a different approach to product development, one that combines or integrates multiple disciplines. “When I was designing the pedalboard, I didn’t see a lot of combined approaches,” he told MD+DI. His experience prompted the idea of a multidisciplinary product development firm. “There was an opportunity in the market to offer a process that took a product from start to finish. A holistic view was necessary to achieve this. We needed to un...
Source: MDDI - January 12, 2018 Category: Medical Devices Authors: Daphne Allen Tags: MD & M West (Anaheim) Medical Device Business Source Type: news

Boston Scientific touts spinal cord stim pain-relief trial
This study provides data on people who have suffered with chronic pain for years and who pose some of the biggest challenges in the long-term use of SCS. The results demonstrated that giving patients the choice to use sub-perception or paresthesia-based therapy provides superior patient outcomes and affirms that SCS is a clinically valuable treatment option.” The trial showed that if patients are able to choose the type of therapy that brings them the most effective pain relief, the number of people whose pain was effectively controlled by SCS jumped by 62%. More than half of the patients in one of the study’s ...
Source: Mass Device - January 12, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Neuromodulation/Neurostimulation Pain Management Spinal Wall Street Beat Boston Scientific Source Type: news

Stimwave raises $50m for consumer launch of chronic pain neuromod device
Stimwave said this week that it raised more than $50 million from a consortium of unnamed investors for the consumer launch of its Freedom neuromodulation device for treating chronic pain. Pompano Beach, Fla.-based Stimwave said the Freedom stimulator is the sole FDA-approved wireless, micro-sized device cleared for treating neuropathic pain. The device uses a tiny injectable microchip to deliver small pulses of energy to nearby nerves to relieve pain. “The key to Stimwave pain management is the ability to allow the pain sufferer to control their pain wherever and whenever they want,” chairwoman and c...
Source: Mass Device - January 12, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Funding Roundup Neuromodulation/Neurostimulation Pain Management Stimwave Source Type: news

Endo Pharmaceuticals hit with subpoena over opioid products
Endo Pharmaceuticals (NSDQ:ENDP) was hit by a grand jury subpoena yesterday from the U.S. Attorney’s Office for the Southern District of Florida over its oxymorphone products. The subpoena requests an array of documents, including those derived from past or pending lawsuits, product safety and efficacy, overdoses, diversion, theft, abuse and misuse, withdrawal and addictiveness. Get the full story at our sister site, Drug Delivery Business News. The post Endo Pharmaceuticals hit with subpoena over opioid products appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - January 12, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Food & Drug Administration (FDA) Legal News Pain Management Pharmaceuticals Wall Street Beat Endo Pharmaceuticals Source Type: news

Medtronic Tweaks its New Pain Pump System
FDA approved a new clinician programmer for use with Medtronic's SynchroMed II intrathecal drug delivery system, an implantable pump that provides targeted drug delivery for patients suffering from chronic pain and severe spasticity. The new technology was designed to simplify therapy management for clinicians by providing them with visual tools and intuitive workflows. The SynchroMed II clinician programmer is a new application that can be used on a tablet and features visual enhancements for a side-by-side comparison of therapy changes. The new app also communicates wirelessly to the SynchroMed II pump with automate...
Source: MDDI - January 12, 2018 Category: Medical Devices Authors: Kristopher Sturgis Tags: Implants Source Type: news

How medtech could stop the drug overdose crisis in the U.S.
[Image from The.Comedian on Flickr]The opioid epidemic is one of the deadliest problems facing the U.S. today. Through the development of new pain management devices, medtech could be a leader in solving the crisis. The prescription opioid overdose crisis in America didn’t start until the late 1990s, when pharmaceutical companies touted prescription painkillers that weren’t supposed to be addictive. As a result, medical professionals more frequently prescribed opioid painkillers. Since then, opioid-related deaths have seen a steady increase. From 2000 to 2014, nearly half a million Americans died from a drug ov...
Source: Mass Device - January 11, 2018 Category: Medical Devices Authors: Danielle Kirsh Tags: Hospital Care mHealth (Mobile Health) Pain Management Patient Monitoring Avancen Halyard Health MedTech Myoscience nevro opioid crisis Regenesis Biomedical Inc. Source Type: news

Braeburn raises $110m for opioid use disorder depot injection
Braeburn Pharmaceuticals has raised $110 million in a mezzanine round of financing led by Wellington Capital. Other investors included Avista Capital Parnters, RA Capital Management, Deerfield Management and Apple Tree Partners. The Princeton, N.J.-based company said it plans to use the new funds to support the FDA approval process and commercialization of CAM2038, a weekly and monthly buprenorphine depot injection designed to treat adults with opioid use disorder. Get the full story at our sister site, Drug Delivery Business News. The post Braeburn raises $110m for opioid use disorder depot injection appeared first o...
Source: Mass Device - January 11, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Funding Roundup Pain Management Pharmaceuticals Braeburn Pharmaceuticals Source Type: news

Pain management app Manage My Pain deployed in four Ontario clinics
Correction: A previous version of this text misstated the source of the funding.   (Source: mobihealthnews)
Source: mobihealthnews - January 10, 2018 Category: Information Technology Source Type: news

Medtronic launches post-market SCS programming study
Medtronic (NYSE:MDT) said today it launched a post-market clinical study of its Evolve SM workflow spinal cord stimulation optimization program, having enrolled the first patient in the study. The first patient in the trial was enrolled at Wilmington, Del.’s Center for Interventional Pain & Spine, the company said. “Our goal is to improve or restore function. Even with all of today’s technological advances, chronic pain can be challenging to manage; this is further complicated by the opioid crisis. Standard treatment guidance has the potential to help optimize pain relief, and the Vectors Post Ma...
Source: Mass Device - January 9, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Neuromodulation/Neurostimulation Pain Management Medtronic Source Type: news

Nevro wins FDA nod for next-gen Senza II SCS
Nevro Corp. (NYSE:NVRO) said yesterday it won FDA approval for its next-generation Senza II spinal cord stimulation system. The Redwood City, Calif.-based company said the Senza II SCS system is designed to deliver HF10 therapy through a smaller footprint while maintaining the durability and performance of the current generation device. Both the next-gen device and previous versions are designed to deliver high-frequency electrical impulses of up to 10,000Hz  to the spinal cord to avoid the tingling sensation known as paresthesia that bothers some SCS patients, Nevro said. “My colleagues and I are...
Source: Mass Device - January 9, 2018 Category: Medical Devices Authors: Fink Densford Tags: Neuromodulation/Neurostimulation Pain Management Regulatory/Compliance nevro Source Type: news

Lymphedema after cancer treatment -- special issue of Rehabilitation Oncology presents research update
(Wolters Kluwer Health) Individuals who have been treated for cancer are at risk for a complication called lymphedema: swelling in the body region where lymph nodes were removed, causing pain and limited function. New research and insights on the management of cancer-related lymphedema are presented in the January special issue of Rehabilitation Oncology, official journal of the Oncology Section of the American Physical Therapy Association. The journal is published by Wolters Kluwer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 4, 2018 Category: Cancer & Oncology Source Type: news

Posters Accepted at CNS Summit 2017 and NANS 2018 Meetings
CME Outfitters is excited to be presenting findings from their PredictCME analysis of educational outcomes data on intrathecal pain management.(PRWeb January 04, 2018)Read the full story at http://www.prweb.com/releases/2018/01/prweb15055551.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 4, 2018 Category: Pharmaceuticals Source Type: news

Egalet teams up with Valeant division to promote pain-relief nasal spray
Egalet (NSDQ:EGLT) has partnered with a division of Valeant Pharmaceuticals (NYSE:VRX), OraPharma, to co-promote its pain-relief nasal spray to dentists and oral surgeons in the U.S. Sprix nasal spray is a nonsteroidal anti-inflammatory drug designed for the short-term management of moderate to moderately-severe pain. Get the full story at our sister site, Drug Delivery Business News. The post Egalet teams up with Valeant division to promote pain-relief nasal spray appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - January 3, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Pain Management Pharmaceuticals Wall Street Beat egalet Valeant Pharmaceuticals Source Type: news

The Effect of Swaddling During Heel Lance in Newborns The Effect of Swaddling During Heel Lance in Newborns
Does swaddling help soothe newborns and reduce pain during the heel lance procedure?Pain Management Nursing (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 2, 2018 Category: Consumer Health News Tags: Nursing Journal Article Source Type: news

Pavmed offers warrants at half-price to raise cash for carpal tunnel syndrome device
Pavmed (NSDQ:PAVM) said this week that it plans to temporarily cut the exercise price of its outstanding Series W warrants in half. Each of the New York-based company’s outstanding warrants is currently exercisable at $5.00 apiece for one share of common stock. After Pavmed files tender offer materials, each warrant will have an exercise price of $2.50 per share. The company said it expects the offer will be good for 20 business days, but it could decide to extend the deal. “Pavmed is providing this opportunity to exercise warrants at a reduced price in order to encourage holders to exercise a meaningful p...
Source: Mass Device - December 29, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Funding Roundup Pain Management Wall Street Beat Pavmed Source Type: news